Literature DB >> 19142865

Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients.

Meenakshi Sawhney1, Ajay Matta, Muzafar A Macha, Jatinder Kaur, Siddhartha DattaGupta, Nootan K Shukla, Ranju Ralhan.   

Abstract

Activated leukocyte cell adhesion molecule (ALCAM) has been proposed to function as a cell surface sensor for cell density, controlling the transition between local cell proliferation and tissue invasion in cancer progression. Herein, we determined ALCAM expression in 107 oral squamous cell carcinomas (OSCCs), 78 oral lesions (58 hyperplasias and 20 dysplasias) and 30 histologically normal oral tissues using immunohistochemistry and correlated with clinicopathological parameters. Significant increase in ALCAM immunopositivity was observed from normal oral mucosa, hyperplasia, dysplasia to OSCCs (p(trend) < 0.001). Increased ALCAM expression was observed in cytoplasm of epithelial cells as early as in hyperplasia (p = 0.001, OR = 3.8). Sixty-five of 107 (61%) OSCCs showed significant overexpression of ALCAM protein in cytoplasm/membrane of tumor cells (p = 0.043; OR = 3.3) in comparison with the normal oral tissues. Among OSCCs, cytoplasmic ALCAM was associated with advanced tumor size, tumor stage and tobacco consumption. Importantly, cytoplasmic ALCAM was an independent predictor of poor prognosis of OSCCs in multivariate analysis (p = 0.012, OR = 6.2). In an attempt to understand the molecular basis of cytoplasmic localization of ALCAM, 14-3-3 zeta and 14-3-3 sigma were identified as its novel binding partners in oral cancer cells. In conclusion, increased expression of ALCAM is an early event in oral tumorigenesis; its cytoplasmic accumulation in tumor cells is a predictor of poor prognosis of OSCCs, underscoring its potential as a candidate prognostic marker for oral cancer. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19142865     DOI: 10.1002/ijc.24192

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors.

Authors:  Katelyn E McCabe; Bin Liu; James D Marks; James S Tomlinson; Hong Wu; Anna M Wu
Journal:  Mol Imaging Biol       Date:  2012-06       Impact factor: 3.488

2.  Plasma membrane proteomics of tumor spheres identify CD166 as a novel marker for cancer stem-like cells in head and neck squamous cell carcinoma.

Authors:  Ming Yan; Xihu Yang; Lizhen Wang; David Clark; Hui Zuo; Dongxia Ye; Wantao Chen; Ping Zhang
Journal:  Mol Cell Proteomics       Date:  2013-07-31       Impact factor: 5.911

3.  ALCAM: Basis Sequence: Mouse.

Authors:  Amanda G Hansen; Guido W Swart; Andries Zijlstra
Journal:  AFCS Nat Mol Pages       Date:  2011

4.  Clinical implication of CD166 expression in salivary gland tumor.

Authors:  Azadeh Andisheh-Tadbir; Mohammad Javad Ashraf; Bijan Khademi; Shahab Ahmadi
Journal:  Tumour Biol       Date:  2014-12-04

5.  A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth.

Authors:  Merete Thune Wiiger; Hege B Gehrken; Øystein Fodstad; Gunhild M Maelandsmo; Yvonne Andersson
Journal:  Cancer Immunol Immunother       Date:  2010-07-16       Impact factor: 6.968

6.  Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients.

Authors:  Maike Ihnen; Kerstin Kress; Jan Felix Kersten; Ergin Kilic; Matthias Choschzick; Hilke Zander; Volkmar Müller; Sven Mahner; Fritz Jänicke; Linn Woelber; Karin Milde-Langosch
Journal:  BMC Cancer       Date:  2012-04-04       Impact factor: 4.430

7.  CIAPIN1 nuclear accumulation predicts poor clinical outcome in epithelial ovarian cancer.

Authors:  Xiaolan Cai; Jian Wang; Xiaoyan Xin
Journal:  World J Surg Oncol       Date:  2012-06-19       Impact factor: 2.754

8.  Guggulsterone targets smokeless tobacco induced PI3K/Akt pathway in head and neck cancer cells.

Authors:  Muzafar A Macha; Ajay Matta; Shyam Singh Chauhan; K W Michael Siu; Ranju Ralhan
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

9.  Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells.

Authors:  Jing Jiao; Antreas Hindoyan; Shunyou Wang; Linh M Tran; Andrew S Goldstein; Devon Lawson; Donghui Chen; Yunfeng Li; Changyong Guo; Baohui Zhang; Ladan Fazli; Martin Gleave; Owen N Witte; Isla P Garraway; Hong Wu
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

10.  Clinical significance of altered expression of β-catenin and E-cadherin in oral dysplasia and cancer: potential link with ALCAM expression.

Authors:  Jatinder Kaur; Meenakshi Sawhney; Siddhartha DattaGupta; Nootan Kumar Shukla; Anurag Srivastava; Paul G Walfish; Ranju Ralhan
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.